Abstract:According to global cancer data, lung cancer was the leading cause of cancer-related death in 2020. With the diversification of treatment strategies, the survival outcomes of patients with advanced lung cancer have improved significantly, but the 5-year overall survival rate remains <20%. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferred treatment for lung adenocarcinoma patients with EGFR-sensitive mutations; however, acquired drug resistance is inevitable. Osimertinib (a third-generation EGFR inhibitor) is the most commonly used drug for cancers with a secondary T790M mutation. Unfortunately, acquired drug resistance against third-generation drugs still emerges. The C797s mutation is the primary acquired resistance mechanism against Osimertinib. Research on fourth-generation EGFR-TKI drugs with a C797s mutation is currently at various experimental stages, and no drug has been approved for clinical use. In addition to the resistance mechanisms described above, HER2 amplification, MET amplification, PIK3A mutation, KRAS mutation, BRAF mutation, transformation to small cell lung cancer, transformation to lung squamous cell carcinoma, and EMT have been reported as mechanisms of acquired drug resistance to first-, second- and third-generation EGFR-TKIs. These mechanisms are noted in a relatively high proportion of tumors, but treatment options are limited. In recent years, immunotherapy has made progress in the treatment of several cancers, including advanced EGFR-mutated non-small cell lung cancer (NSCLC). Due to the relatively high frequency of EGFR mutation in patients with lung adenocarcinoma in China, an increased number of patients develop EGFR-TKI resistance, and subsequent treatment options are critical. This article reviews the mechanisms of drug resistance to different EGFR-TKIs and treatment progression, providing ideas for the follow-up treatment for EGFR-resistant patients.

Advances in mechanism of drug resistance to EGFR-TKIs for non-small cell lung cancer and possible solutions

Advances of Autophagy and EGFR-TKI Drug Resistance in the Treatment of Non-Small Cell Lung Cancer

EGFR-TKI Resistance in NSCLC Patients: Mechanisms and Strategies.

Strategies to Improve Outcomes of Patients with EGFR-Mutant Non–Small Cell Lung Cancer: Review of the Literature

Updates on Resistance Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-cell Lung Cancer

Research progress of the mechanisms on the drug-resistance of EGFR-TKIs in non-small cell lung cancer

Progress of EGFR-targeted Therapy for NSCLC

Advances in research on EGFR-TKI resistance mechanism and therapeutic strategies in non-small cell lung cancer

Mechanisms of resistance to EGFR TKIs and therapeutic perspectives in non-small cell lung cancer

Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy

Targeted Therapy for Non-Small-cell Lung Cancer Using EGFR-TKIs

Mechanism and Treatment Associated with Resistance to EGFR-TKI

[Research Progress on Resistance Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer].

[Research Progress of the Role of EMT in EGFR-TKIs Resistance of Non-small Cell Lung Cancer].

Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer

Overcoming EGFR-TKI resistance by targeting the tumor microenvironment

Drug resistance mechanisms and progress in the treatment of EGFR-mutated lung adenocarcinoma

The resistance mechanisms and treatment strategies for EGFR-mutant advanced non-small-cell lung cancer.

Novel considerations on EGFR-based therapy as a contributor to cancer cell death in NSCLC

Immunotherapy-based Combination Strategies for Treatment of EGFR-TKI-resistant Non-Small-cell Lung Cancer